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Amino acidsPiperine, an alkaloid present in the Piper genus, was shown to have an anticonvulsant activity, evaluated by
the pilocarpine-induced model, in mice. Pilocarpine (350 mg/kg, i.p.) was administered 30 min after piperine
(2.5, 5, 10 and 20 mg/kg, i.p.) which signiﬁcantly increased latencies to 1st convulsion and to death, and per-
centage of survivals. These parameters were also increased in the pilocarpine groups pretreated with atro-
pine plus piperine (10 and 2.5 mg/kg, respectively), as related to the pilocarpine group. However, they
were not altered in the pilocarpine groups pretreated with memantine (a NMDA-type glutamate receptors
blocker, 2 mg/kg, p.o.) or nimodipine (a calcium channel blocker, 10 mg/kg, p.o.), both associated with piperine
(1 or 2.5 mg/kg), as compared to the piperine plus pilocarpine group. Moreover, the pilocarpine group
pretreated with diazepam (which binds to the GABAA receptor, 0.2 and 0.5 mg/kg, i.p.) plus piperine (1 and
2.5 mg/kg) signiﬁcantly increased latency to the 1st convulsion, as related to the pilocarpine group, suggesting
that the GABAergic system is involved with the piperine action. Furthermore, the piperine effect was blocked
by ﬂumazenil (2 mg/kg, i.p.), a benzodiazepine antagonist. Untreated P350 animals showed decreased striatal
DA and increased DOPAC and HVA levels that were not affected in the piperine plus pilocarpine groups. Piperine
increased striatal levels of GABA, glycine and taurine, and reversed pilocarpine-induced increases in nitrite
contents in sera and brain. Hippocampi from the untreated pilocarpine group showed an increased number of
TNF-α immunostained cells in all areas, as opposed to the pilocarpine group pretreated with piperine. Taken
together, piperine anticonvulsant effects are the result of its anti-inﬂammatory and antioxidant actions, as
well as TNF-α reduction. In addition, piperine effects on inhibitory amino acids and on the GABAergic system
may certainly contribute to the drug anticonvulsant activity.
© 2013 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Piperine (PPR), a piperidine alkaloid, is a major component of plants
from the Piper genus (Piperaceae family), as Piper nigrum, Piper longum
and Piper tuberculatum. It is known to present several pharmacological
properties, as anti-inﬂammatory, antifertility and stimulator of seroto-
nin synthesis in the central nervous system, among others (Daware
et al., 2000; Kim and Lee, 2009; Vijayakumar and Nalini, 2006). Piperine
is an inhibitor of themicrosomal system for drugmetabolization, and
was shown to be a selective noncompetitive inhibitor of CYP3A4. The
family of the cytochrome P450 (CYP450) enzyme system is the major
catalyst of oxidative biotransformation reactions involved in drug me-
tabolism, and the subtype CYP3A4 is the most prevalent cytochrome,0/1100, 60170-020 Fortaleza,
ana).
vier OA license. accounting for 30–50% of drugs metabolized by type I enzymes
(Haddad et al., 2007; Volak et al., 2008). Thus, there are several stud-
ies focusing on piperine bioavailability enhancing properties (Shaikh et
al., 2009; Srinivasan, 2007). On the other hand, only a few and very
earlier studies are related to piperine anticonvulsant effects and its pos-
sible mechanism of action (D'Hooge et al., 1996).
Epilepsy is the commonest neurological condition, characterized by
spontaneous recurrent seizures, triggered by abnormal electrical activ-
ity in the brain cortex. The involvement of hyperexcitable neurons links
the pathogenesis of epilepsy and the generation of synchronized neuro-
nal activity with an imbalance between inhibitory GABA-mediated and
excitatory (glutamate-mediated) neurotransmission (Dalby and Mody,
2001).
Currently, there is a great availability of drugs in clinics for epilepsy
management. However, most of them are alternatives or 2nd choices,
pointing out to the need for new safer and more efﬁcacious drugs for
that neurologic condition. Thus, drug-resistant seizures pose a great
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interventions for seizure disorders, the incidence of epilepsies andmor-
tality associated to status epilepticus (SE) remain elevated (Marchi et
al., 2011). Acute and chronic toxicities complicate all antiepileptic
drugs (AEDs) and are idiosyncratic ones. An earlier study shows that
three major chronic toxicities of AEDs have been noted, such as soft
tissue and gumhypertrophy, progressive ataxia, andperipheral neurop-
athy. New AEDs require careful post-marketing surveillance, since all
of them have some adverse effects which differ in type and severity
(Cramer et al., 2010).
Inﬂammation is known to participate in the mediation of a grow-
ing number of acute and chronic neurological disorders, including ep-
ilepsy. Thus, inﬂammatory processes, as activation of microglia and
astrocytes, production of proinﬂammatory cytokines and related mol-
ecules, have been described in human epilepsy as well as in experi-
mental models of epilepsy (Choi and Koh, 2008).
The objectives of the present studywere to evaluate the effects of pip-
erine, alone and associated to atropine (ATRP), memantine (MEMT),
nimodipine (NIMO), diazepam (DZP) and ﬂumazenil (FLUM), on the
model of pilocarpine-induced convulsions in mice, attempting to clarify
the PPR anticonvulsive mechanism of action. Besides, considering the
relationship of this drug effect with the anti-inﬂammatory and antioxi-
dant properties, its action on brain monoamines, amino acids and cyto-
kines (TNF-alpha) were also pursued.
2. Material and methods
2.1. Drugs and reagents
Piperine, pilocarpine, cremophor, atropine, standard monoamines
and amino acids were purchased from Sigma-Aldrich, USA. Memantine
was from Apsen, Brazil; nimodipine from EMS S/A, Brazil; diazepam
from Hipolabor, Brazil; and ﬂumazenil, morphine and naloxone from
Laboratório Cristália, Brazil. All other reagents were of analytical grade.
2.2. Animals and experimental protocol
Male Swiss mice (25–30 g) were provided by the Animal House
of the Faculty of Medicine Estácio of Juazeiro do Norte (FMJ), Ceará,
Brazil. The animals were housed into plastic cages with sawdust as
beddings, and kept in a room with controlled temperature (25±
2 °C) under a 12 h/12 h light/dark cycle, and food and water supplied
ad libitum. The animals were acutely administered with piperine
(PPR: 2.5, 5, 10 and 20 mg/kg, i.p.), followedby the pilocarpine injection
(P: 350 mg/kg) 30 min later. PPR was suspended in a 2% Cremphor
aqueous solution, immediately before use. For the associations proto-
cols, the following drugs were administered 15 min before PPR (i.p.),
therefore 45 min before P350 (i.p): ATRP (i.p.), MEMT (p.o.), DZP
(i.p.) and NIMO (p.o.). In the FLUM (i.p.) association, PPR (i.p) and
FLUM (i.p) were administered 45 and 30 min, respectively, before
P350. The experiments were carried out according to the Guide for
the Care andUse of Laboratory Animals of theU.S. Department of Health
and Human Services. The project was previously approved by the
Animal Ethics Committee of the Faculty of Medicine of the Federal Uni-
versity of Ceará, Barbalha, Ceará, Brazil.
2.3. Behavioral testing: pilocarpine-induced convulsions model
The systemic injection of a high dose of pilocarpine is one of the
most common models for evoking SE and subsequent epilepsy in ro-
dents, and results in severe brain damage (Cavalheiro et al., 2006).
Mice (8–27 animals in PPR-treated groups and 39 animals in the
P350 group) were distributed into the following groups: pilocarpine
(P: 350 mg/kg, i.p.) and PPR+P350 (PPR: 1, 2.5, 5, 10 or 20 mg/kg, i.p.)
followed by pilocarpine, 30 min later. The association experiments
were: 1. ATRP1+PPR1; ATRO10+PPR2.5; 2. MEMT2+PPR2.5; 3.NIMO10+PPR2.5; 4. DZP0.2+PPR1;DZP0.5+PPR2.5; 5. FLUM2+PPR5.
The observed parameters were: latency to the ﬁrst convulsion and
latency to death (up to 2 h). Besides, the number of survival animals
was also determined (for this, the animals were observed for 24 h).
For monoamine and amino acid experiments, as well as immunohis-
tochemistry assays for TNF-alpha, the animals were sacriﬁced by decap-
itation after the 1st convulsion (usually 30 min in the P350 group and
2 h in PPR+P350 groups). These two times were chosen since the
animals from P350 groups did not survive longer than 30 min. They
were thus decapitated immediately after their 1st convulsion or death.
On the other hand, groups pretreated with PPR prior to P350 were
sacriﬁced after their 1st convulsion (2 h cut off time). The brains were
dissected for isolation of striata and preparation of homogenates, in the
cases of monoamine and amino acid determinations. For TNF-alpha
immunohistochemistry assays, sections of hippocampi were processed,
as described below.
2.4. Monoamine levels determination
For measurements of dopamine (DA) and their metabolites (3,4
dihydroxyphenylacetic acid — DOPAC and homovanilic acid — HVA),
striata from all groups after pilocarpine-induced convulsions, untreated
(P350) or pretreated with PPR (PPR+P350), were used to prepare
10% homogenates. These were sonicated in 0.1 M HClO4, for 30 s,
centrifuged at 4 °C for 15 min, at 15,000 rpm, and the supernatants
were ﬁltered (0.2 μm, Millipore). Twenty-microliter samples were
then injected into a high-performance liquid chromatograph (HPLC)
column (C18, 250×4.6 mm, 5 μm) and a 0.6 mL/min ﬂow rate. The
mobile phase was 0.163 M citric acid, pH 3.0, containing 0.02 mM
EDTAwith 0.69 mMsodiumoctanesulfonic acid (SOS), as an ion pairing
reagent, 4% v/v acetonitrile and 1.7% v/v tetrahydrofuran. The mono-
amines were electrochemically detected, using an amperometric detec-
tor (Shimadzu, Japan), by oxidation on a glassy carbon electrode at
0.85 V, relatively to the Ag–AgCl reference electrode. Their concentra-
tions were determined by comparison with standards injected into
the HPLC column at the day of experiment, and the values expressed
as ng/g tissue.
2.5. Amino acid determinations
Amino acid concentrationswere determined by reversed-phase high
performance liquid chromatography (RP-HPLC), involving pre-column
derivatization with orthophthalaldehyde (OPA). The Shimadzu RP-
HPLC system (Japan) consisted of a spectroﬂuorimeter detector (ex-
citation and emission wavelengths of 350 and 450 nm, respectively)
coupled with an integrator. The chromatographic column used was a
C18 (250×4.6 mm, 5 μm) with a 1 mL/min ﬂow rate, and the mobile
phase A had the following composition: 50 mM NaH2PO4 solution in
20% methanol, pH 5.5; the mobile phase B was 100% methanol. Both
phases were prepared in ultra pure water (Milli-Q system) and ﬁltered
through 0.22 μm ﬁlters from Millipore. A 2.5 mM stock solution of
standard amino acids was prepared in the mobile phase A. Brain ho-
mogenates (at 10%)were prepared in 0.1 Mperchloric acid, centrifuged
(25,000×g, 30 min), and the supernatants collected andﬁltered. For the
derivatization solution, 13.5 mg OPA were dissolved in 250 μL ethanol,
followed by the addition of 10 μL 2-mercaptoethanol, and the volume
was completed to 2.25 mL with borate buffer, pH 9.3. The solution
was then ﬁltered through a 0.22 μm ﬁlter (Millipore) and used after
24 h. For derivatizations, 20 μL amino acids or samples were diluted
with 20 μL OPA, and injected into the HPLC column, 1 min later.
2.6. Nitrite determinations in the blood and brain cortex of mice treated
with PPR and submitted or not to pilocarpine-induced convulsions
The bloodwas collected from the retro-orbital plexus and centrifuged
(3000 rpm, 10 min) for the separation of sera, after the animal's 1st
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in the PPR+P350 groups). For the brain cortex, a 10% homogenate
(in saline) was centrifuged (5000 rpm, 20 min). Then, 100 μL of 10%
picric acid were added to the supernatants for protein precipitation,
followed by centrifugation (14,000 rpm for 30 min)whose supernatants
were then used for nitrite determination by the method of Green et
al. (1981). For this, 100 μL Griess reagent (1% sulphanilamide/0.1%
N-(1-naphthyl)-ethylenediamine hydrochloride/1% H3PO4/distilled
water, 1:1:1:1) were added to 100 μL serum or brain cortex superna-
tants, followed by 10 min incubation at room temperature. The standard
curve was made with concentrations of NaNO2, ranging from 0.75 to
100 μM, under the same conditions. Blanks were prepared by the addi-
tion of 100 μL Griess reagent to 100 μL serum, and the absorbance deter-
mined at 560 nm.
2.7. Immunohistochemistry assay for TNF-alpha in hippocampi from
mice submitted to pilocarpine-induced convulsions
For TNF-α immunohistochemistry assays, three groups of 3 mice
each were treated with P350 or with PPR (5 and 10 mg/kg, i.p.)
followed by P350, 30 min later. The animals were sacriﬁced after
the 1st convulsion (usually 30 min in the P350 group, and 2 h in
the PPR+P350 groups), for brain dissection. Then, hippocampal sec-
tions were immersed in buffered formalin solution for 24 h, followed
by immersion in 70% ethanol. The sections were then deparafﬁnized,
dehydrated in xylol and ethanol, and immersed in 0.1 M citrate buffer
(pH 6) under microwave heating (18 min), for antigen recovery.
After cooling at room temperature (20 min), sections were washed
with a phosphate buffered saline (PBS), followed by a 15 min block-
ade of endogenous peroxidase with a 3% H2O2 solution. The sections
were incubated overnight (4 °C) with rabbit primary antibodies
(anti-TNF-α, 1:200 dilutions in PBS-BSA). At the next day, the sec-
tions were washed in PBS, and incubated for 30 min with the second-
ary biotinylated rabbit antibody (anti-IgG, 1:200 dilution in PBS-BSA).
After washing in PBS, the sections were incubated for 30 min with
the conjugated streptavidin peroxidase complex (ABCVectastain®com-
plex, Vector Laboratories, Burlingame, CA, USA). After another washing
with PBS, the sections were stained with 3,3′diaminobenzidine-
peroxide (DAB) chromophore, counter-stained with Mayer hematoxy-
lin, dehydrated and mounted in microscope slides for analyses.
2.8. Statistical analyses
The data for latencies to the 1st convulsion and to death (pilocar-
pine and piperine+pilocarpine groups) were analyzed by the
non-parametric Kruskal–Wallis test, followed by the Dunn's as a post
hoc multiple comparisons test, and the frequency to death by the
Log-rank (Mantel–Cox) test. Chi-square and p values were estimatedTable 1
Ratios and percentages of development of convulsions and survivals, after pilocarpine-indu
Treatments before P350
P350 PPR 1
Number of convulsed animals up to 90 min after P350 38/39
(97%)
18/18
(100%)
Survivors up to 24 h after P350-induced convulsions 1/38
(3%)
3/18
(17%)
Latency to 1st convulsion (seconds) 700.2±20.1 701.6±52.5
Latency to death (seconds) 1130±45.3 1171±109.3
The animals were treated with distilled water or piperine (PPR: 1, 2.5, 5, 10 or 20 mg/kg, i.p
1st convulsion and to death are represented by means±S.E.M. (seconds), after P350 admin
test. Latency to 1st convulsion: **pb0.01 and ***pb0.001 vs. P350. Latency to death: *p
nonparametric Log-rank (Mantel–Cox) test (comparison of each survival curve to P350): a
pb0.0001; all versus P350.for each two survival curves. Two-way ANOVA (ﬁgures from GraphPad
Prism 5), followed by the Mack–Skillings statistical test (a non-
parametric Two-way ANOVA used for incomplete block designs)
and by the Dwass–Steel–Critchlow–Fligner test for multiple compar-
isons were used (XLSTAT), for the association experiments with two or
more drugs. All other cases were analyzed with One-way ANOVA,
followed by the Student–Newman–Keuls as the test post hoc. The re-
sults were considered signiﬁcant at pb0.05.
3. Results
3.1. Behavioral testing
3.1.1. PPR effects on the development of pilocarpine-induced convulsions
Piperine, at the doses of 2.5, 5, 10 and 20 mg/kg, administered
(i.p.) 30 min before pilocarpine (PPR+P350), showed an anticonvul-
sant effect reducing the percent of mice that convulsed from 97%
(P350) to 81, 85, 76 and 80%, respectively (Table 1). At the same
doses, PPR signiﬁcantly increased by 31, 65, 55 and 109%, respectively,
the latency to the 1st convulsion, as compared to the P350 group
(Fig. 1A). The PPR1+P350 showed no signiﬁcant difference from the
P350 group (Table 1).
3.1.2. PPR effects on mice mortality rate after pilocarpine-induced
convulsions
Ninety seven percent of mice that developed convulsions, died, up
to 30 min after P350 administration. All piperine doses, increased
from 17 to 63% the percentage of survivals 24 h after the 1st convul-
sion in a dose-dependent manner (Table 1). Among the animals that
had convulsed and died, piperine at all doses, but not at 1 mg/kg, in-
creased the latency to death from 58 to 138% (Fig. 1B).
3.1.3. PPR effects after its association to atropine, memantine,
nimodipine, diazepam and ﬂumazenil
In order to clarify the mechanism for the PPR anticonvulsive effect,
these behavior tests were further carried out with the P350 group
pretreated with atropine (ATRP, a muscarinic antagonist), memantine
(MEMT, a NMDA-type glutamate receptor blocker), nimodipine (NIMO,
a Ca2+ channel blocker), diazepam (DZP, a drugwhichbinds to a speciﬁc
subunit of the GABAA receptor) and ﬂumazenil (FLUM, a benzodiazepine
antagonist) plus PPR (1 or 2.5 mg/kg).
Association to atropine (ATRP): although not signiﬁcant (probably due
to the fact that a large number of animals did not convulse), a trend
for an increase in the latency to the 1st convulsion was seen in P350
groups pretreated either with PPR2.5, ATRP10 or the association of
PPR2.5+ATRP10 as related to the untreated P350 group. Besides, in the
last two groups, convulsing animals did not die, and these data wereced (P350) convulsions, in mice pretreated with piperine (PPR).
PPR 2.5 PPR 5 PPR 10 PPR 20
17/21
(81%)
23/27
(85%)
16/21
(76%)
16/20
(75%)
6/17
(35%)a
9/23
(39%)b
7/16
(44%)c
10/16
(63%)d
921.0±63.8 ⁎⁎ 1156.0±72.6 ⁎⁎⁎ 1088.0±51.8 ⁎⁎⁎ 1460.0±97.5 ⁎⁎⁎
1791±225.4 ⁎ 2220±254.0 ⁎⁎⁎ 2695±336.0 ⁎⁎⁎ 2070±237.7 ⁎⁎
.) and, 30 min later, administered with pilocarpine (P: 350 mg/kg, i.p.). Latencies to the
istration, and analyzed by Kruskal–Wallis, followed by the Dunn's multiple comparison
b0.05, **pb0.01 and ***pb0.001 vs. P350. Data on Survivors were analyzed by the
. χ2=11.08, pb0.0009; b. χ2=13.7, pb0.0002; c. χ2=14.8, pb0.0001; d. χ2=24.42,
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Fig. 1. Piperine (PPR: 5, 10 and 20 mg/kg, i.p.) signiﬁcantly and dose-dependently in-
creases latencies to the ﬁrst convulsion (A) and to death (B) of pilocarpine-induced
convulsions in mice. Pilocarpine (P: 350 mg/kg, i.p.) was administered to mice, 30 min
after their pretreatments with PPR. The data are means±S.E.M. for latencies to the 1st
convulsion and to death (20 to 39 animals per group). Latency to the 1st convulsion:
*pb0.05 and ***pb0.001 vs. P350. Latency to death: **pb0.01 and ***pb0.001 vs. P350
(Kruskal–Wallis followed by Dunn's multiple comparison test).
La
te
nc
y 
(s)
1s
t C
on
vu
lsi
on
De
ath
0
500
1000
1500
2000
2500
P350 PPR1 ATR2 PPR1+ATRP2
PPR2.5 ATRP10 PPR2.5+ATRP10
Fig. 2. Effects of piperine (PPR: 1 and 2.5 mg/kg, i.p.) isolated or in association with
atropine (ATRP: 2 and 10 mg/kg, i.p.), respectively, on the latency to pilocarpine
(P: 350 mg/kg, i.p.)-induced 1st convulsion and death. ATRP was administered
15 min before PPR and 45 min prior to P350. The data represent means±S.E.M. for la-
tency to the 1st convulsion and death (6 to 18 and 3 to 14 animals per group, respec-
tively). No signiﬁcant differences among treatments were observed (Skillings–Mack
non-parametric Two-way ANOVA, followed by the Dwass–Steel–Critchlow–Fligner
test for multiple comparisons).
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Fig. 3. Effects of piperine (PPR: 2.5 mg/kg, i.p.) isolated or in association with memantine
(MEMT: 2 mg/kg, p.o.), on latencies to pilocarpine (P: 350 mg/kg, i.p.)-induced 1st
convulsion and death. MEMT2 was administered 15 min before PPR2.5 and 45 min
prior to P350. The data represent means±S.E.M. for latencies to the 1st convulsion and
to death (6 to 18 animals per group). No signiﬁcant differences among treatments were
observed (Skillings–Mack non-parametric Two-way ANOVA, followed by the Dwass–
Steel–Critchlow–Fligner test for multiple comparisons).
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differences in the latency to the 1st convulsion among PPR1, ATRP2 and
PPR1+ATRP2 groups and no potentiation of the PPR anticonvulsive ac-
tion by ATRP (Fig. 2).
Association to memantine (MEMT): The memantine pretreatment was
not able to avoid pilocarpine-induced convulsions and, thus, no signiﬁ-
cant increase in the latency to the 1st convulsion was observed in
the P350 group pretreated with the association of PPR2.5+MEMT2,
as related to P350 or MEMT2+P350 groups. A similar result was ob-
served in the latency to death, suggesting no interference of MEMT
with PPR anticonvulsive action (Fig. 3).
Association to diazepam (DZP): signiﬁcant increases in the latency to
the 1st convulsions were observed in PPR2.5, DZP0.5, PPR1+DZP0.2
and PPR2.5+DZP0.5 groups pretreated with P350, as related to the
untreated P350 group, suggesting a potentiation of the PPR effect
by DZP. However, no signiﬁcant differences were noticed in the latency
to death among groups, probably due to the fact that most of the ani-
mals did not convulse nor die after the association of PPR with DZP
(Fig. 4).
Association to ﬂumazenil (FLUM): ﬂumazenil alone or associated
to PPR5 (i.e., FLUM2 or PPR5+FLUM2, drugs administered prior toP350) did not alter the latency to the 1st convulsion or to death, as re-
lated to the untreated P350 group. On the other hand, the P350 group
pretreated with PPR5 signiﬁcantly increased the latency to the 1st con-
vulsion, as compared to the untreated P350 and to P350 groups
pretreated with FLUM2 and PPR5+FLUM2. These results suggest that
ﬂumazenil blockades the anticonvulsant effect of PPR. Furthermore,
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Fig. 4. Effects of piperine (PPR: 1 and 2.5 mg/kg, i.p.) isolated or in association with
diazepam (DZP: 0.2 and 0.5 mg/kg, i.p.), respectively, on the latency to pilocarpine
(P: 350 mg/kg, i.p.)-induced 1st convulsion and death. DZP was administered 15 min
before PPR and 45 min prior to P350. The data represent means±S.E.M. for latency
to 1st convulsion and death (5 to 21 and 2 to 18 animals per group, respectively). Latency
to the 1st convulsion: a. pb0.004 to 0.010 vs. P350 (Skillings–Mack non-parametric
Two-way ANOVA, followed by the Dwass–Steel–Critchlow–Fligner test for multiple
comparisons).
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Fig. 6. Effects of piperine (PPR: 2.5 mg/kg, i.p.) isolated or in association with
nimodipine (NIMO: 10 mg/kg, p.o.), on the latency to pilocarpine (P: 350 mg/kg,
i.p.)-induced 1st convulsion and death. NIMO10 was administered 15 min before
PPR2.5, and 45 min prior to P350. The data represent means±S.E.M. for latency to
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the Dwass–Steel–Critchlow–Fligner test for multiple comparisons).
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the latency to death, as related to the FLUM2 group (Fig. 5).
Association to nimodipine (NIMO): in order to assess the participation of
the Ca2+ channel in the anticonvulsive effect of PPR, nimodipine
(NIMO, 10 mg/kg)was administered alone or associated to PPR2.5, pre-
viously to the pilocarpine injection. An increase in the latency to the 1stLa
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Fig. 5. Effects of piperine (PPR: 5 mg/kg, i.p.) isolated or in association with ﬂumazenil
(FLUM: 2 mg/kg, i.p.), on the latency to pilocarpine (P: 350 mg/kg, i.p.)-induced 1st
convulsion and death. FLUM2 was administered 15 min after PPR5, and 30 min prior
to P350. The data represent means±S.E.M. for latency to the 1st convulsion and to
death (14 to 20 and 5 to 18 animals per group, respectively). Latency to 1st convulsion:
a. pb0.001 PPR5 vs. P350; b. pb0.000 PPR5 vs. FLUM2; c. pb0.036 PPR5+FLUM2 vs.
FLUM2; Latency to death: d. pb0.047 PPR5 vs. FLUM2 (Skillings–Mack non-parametric
Two-way ANOVA, followed by the Dwass–Steel–Critchlow–Fligner test for multiple
comparisons).convulsion was observed in the P350 group pretreated with the as-
sociation of PPR2.5+NIMO10, as compared to the untreated P350
group. In addition, the latency to death was not signiﬁcantly altered in
any of the studied groups, suggesting that the Ca2+ channel does not
have an important role in the PPR anticonvulsive action (Fig. 6).
3.2. Determination of monoamines in mice striata
The untreated P350 group showed a signiﬁcant decrease of 84% in
DA contents, as related to normal controls. This effect persisted in theNo
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Fig. 7. Piperine (PPR: 10 and 20 mg/kg, i.p.) did not reverse the decreases in striatal
DA and their metabolite contents, observed after the pilocarpine-induced convulsions
in mice. Pilocarpine (P: 350 mg/kg, i.p.) was administered, 30 min after D-water
(distilled water, i.p.) or PPR treatments, and the striatawere dissected (for determination
of monoamines) 15 to 60 min afterwards. The columns are means±S.E.M. from 4 to 6
animals per group, analyzed by One-way ANOVA with the Student–Newman–Keuls as a
post-hoc test. DA: ***pb0.001 vs. Normal controls; DOPAC: **pb0.01 vs. Normal control.
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Fig. 9. Piperine (PPR: 5 and 10 mg/kg, i.p.) signiﬁcantly increased GABA and glycine
contents, in mice submitted to pilocarpine-induced convulsions. P350 was adminis-
tered, 30 min after PPR treatments, and the striata were dissected (for amino acid
determinations) 15 to 60 min afterwards. The data are means±S.E.M. for 4 to 6 ani-
mals per group, analyzed by One-way ANOVA with the Student–Newman–Keuls as a
post-hoc test. GABA: **pb0.01 vs. D-water+P350. GLY: *pb0.05 vs. Normal controls
and **pb0.01 vs. D-water+P350.
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the other hand, an opposite effect was observed in DOPAC contents.
Thus, not only in the untreated P350 group but also in the PPR groups,
signiﬁcant increases ranging from 1.8 to 2.1 times were observed
(Fig. 7). Similar results were shown with HVA levels. However, these
data were signiﬁcant only in the untreated P350 group that showed
an increase of 2.1 times in HVA levels, as related to normal controls.
The values of NE remained unchanged in all groups (data not shown).
3.3. Determination of amino acid contents in mice brain areas from P350
groups untreated or treated with PPR
Amino acids determinations were performed in mice striata from
P350 groups untreated or treated with PPR (5, 10 and 20 mg/kg, i.p.).
In the untreated P350 group or in pretreated PPR5 and PPR10 groups,
there were no signiﬁcant differences in GLU contents, when compared
to normal controls. Despite GLU levels in the PPR20+P350 falls
65% when compared to normal control, there were not different
relatively to the untreated P350 group. Except for a signiﬁcant in-
crease in the PPR5+P350 group, as related to the P350 and normal
controls, no other change was noticed in ASP contents (Fig. 8). While
P350 did not change GABA levels, these were signiﬁcantly increased
in the PPR5+P350 and PPR10+P350 groups, as related to untreated
P350 group. Interestingly, in untreated P350 group GLY contents was
decreased in 64%, as related to normal control. Pretreatment with PPR,
completely reversed this reduction (Fig. 9). Although P350 signiﬁcantly
decreased by 71% TAU contents, in relation to normal controls, this ef-
fect was partially reversed in PPR5+P350 and PPR10+P350 groups,
whose valueswere brought towards those of the normal controls. How-
ever, in the PPR20+P350 group, TAUvalueswere similar to those of the
untreated P350 group (Fig. 10).
3.4. Nitrite determination in the blood and brain cortex of mice treated
with PPR and submitted or not to pilocarpine-induced convulsions
The P350 group showed increases of serum nitrite concentrations
around 2.2 fold, as related to normal controls, and these values were
signiﬁcantly lower (ranging from 1.6 to 1.3 fold) in the PPR pretreatedNo
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Fig. 8. Piperine (PPR: 5, 10 and 20 mg/kg, i.p.) did not reverse the glutamate (GLU)
decrease, and only PPR 5 increased aspartate (ASP) contents, both observed in mice
submitted to pilocarpine-induced convulsions. Pilocarpine (P: 350 mg/kg, i.p.) was
administered, 30 min after the D-water (distilled water, i.p.) or PPR treatments, and
the striata were dissected (for amino acid determinations) 15 to 60 min afterwards.
The data are means±S.E.M. for 4 to 6 animals per group, analyzed by One-Way
ANOVA with the Student–Newman–Keuls as a post-hoc test. GLU: *pb0.05 vs. Normal
control; ASP: *pb0.05 to 0.01 vs. all other groups.P350 group. Interestingly, in the all doses of PPR tested, nitrite levels
were close and not signiﬁcantly different from those of normal con-
trols. Similar results were observed for nitrite contents in the brain cor-
tex. Thus, while a 1.4 fold increase in nitrite levels was shown in the
P350 group, lower values were observed in the PPR+350 groups.
Here, only nitrite values in the PPR10+P350 group were similar to
those of normal controls (Fig. 11).3.5. Immunohistochemistry assays for TNF-α in mice hippocampi, from
animals submitted to the pilocarpine-induced convulsions, without
(P350 group) and after piperine pretreatments (PPR+P350 groups)
In Fig. 12 (left column), an intense immunostaining was observed
in all areas (CA1, CA3, DG hippocampus and cortex), indicating theNo
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Fig. 10. Piperine at the lower doses (PPR: 5, and 10 mg/kg, i.p.), but not at 20 mg/kg,
reversed the taurine contents decrease, as showed in the D-water (distilled water,
i.p.)+pilocarpine (P: 350 mg/kg, i.p.) group. P350 was administered to mice, 30 min
after the PPR treatments, and the striata were dissected (for amino acid determina-
tions) 15 to 60 min afterwards. The data are means±S.E.M. for 4 to 6 animals per
group, analyzed by One-way ANOVA with the Student–Newman–Keuls as a post-hoc
test. **pb0.01 vs. D-water+P350.
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Fig. 11. Piperine (PPR: 5, 10 and 20 mg/kg, i.p.) reversed the nitrite content increases in
mice sera and brains, due to pilocarpine-induced convulsions. Pilocarpine (P: 350 mg/kg,
i.p.) was administered to mice, 30 min after distilled water, i.p., or PPR treatments, and
the blood was collected 15 (P350 group) and 60 min (P350 group pretreated with PPR),
after the 1st convulsion. The data are means±S.E.M. for 4 to 7 (sera) or 10 to 12 (brains)
animals per group, analyzed by One-way ANOVA with the Student–Newman–Keuls as a
post-hoc test. Brains and sera: **pb0.01 and ***pb0.001 vs. D-water+P350, respectively.
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group). TNF-α is a pro-inﬂammatory cytokine known to be involved
with convulsions and epilepsy. The piperine pretreatments at both
doses (10 and 20 mg/kg, i.p.) reduced immunostainings for TNF-α
(PPR10+P350 and PPR20+P350 groups, middle and right columns,
respectively), as related to the P350 group. The PPR effect was ob-
served mainly in hippocampal CA1, CA3 and DG areas (three upper
rows, from top to bottom, respectively). In the cortex, the TNF-α immu-
nostained cells were still present in the PPR10+P350 group (fourth
row).4. Discussion
Epilepsy is a neurological disorder characterized by recurrent spon-
taneous seizures and, according to WHO data (Scott et al., 2001), its
incidence rates are very high in the elderly population. Most impor-
tantly it is to know that up to 40% of epileptic patients respond poorly
to conventional pharmacotherapy, and impaired drug uptake into the
brain is considered to be an important contributor to therapeutic failure
(Kwan and Brodie, 2006; Löscher and Potschka, 2005). This makes the
issue of looking for some new, safer and more efﬁcacious therapeutic
agents an urgent need.
Experimental models of seizures and epilepsy have been of great
value for understanding the basic mechanisms underlying ictogenesis
and epileptogenesis, and for contributing to the development of ther-
apeutic alternatives (Marchi et al., 2009). One of the most frequently
usedmodels to evoke SE and subsequent epilepsy is the systemic injec-
tion of pilocarpine in rodents (Cavalheiro et al., 2006). In the present
paper, we studied for the 1st time the anticonvulsant effect of piperine
(PPR) on pilocarpine-induced convulsions in mice.
We showed that PPR signiﬁcantly increases up to 2.3 times both
the latency to the 1st convulsion and to death, as compared to the pi-
locarpine untreated group (P350). Furthermore, PPR signiﬁcantly in-
creased percentages of animals' survivals, as well as of animals showing
no convulsion. Although the anticonvulsant action of PPR in mice was
demonstrated in earlier studies (D'Hooge et al., 1996), those models
used genetic E1 mice or the intra-ventricular injection of kainate, both
associated with higher PPR doses.Even if the direct activation of the cholinergic system by pilocar-
pine in the brain is believed to be the initiating factor for triggering
seizures, this question is not completely solved as yet. Thus, novel ﬁnd-
ings (Marchi et al., 2009) raise the possibility that pilocarpine-induced
seizuresmay also derive from primary proinﬂammatory actions of pilo-
carpine in the periphery. Previously (Marchi et al., 2007), pilocarpine
has been shown to cause acute peripheral proinﬂammatory changes,
leading to blood brain barrier (BBB) leakage, prior to the onset of
SE. The anti-inﬂammatory action of PPR, as already demonstrated by us
in acute models of inﬂammation in the periphery (Cruz et al., 2011), as
well as by others (Bae et al., 2010; Bang et al., 2009; Kumar et al., 2007)
is certainly involved with the anticonvulsant effect of the drug.
In order to clarify the PPR anticonvulsive mechanism of action, the
association of this drug with atropine, a muscarinic antagonist, was
administered tomice before pilocarpine-induced convulsions. The acti-
vation of cholinergic neurons is recognized as the only factor triggering
pilocarpine SE, since the pretreatment with methylscopolamine coun-
teracts most cholinergic effects of systemically injected pilocarpine
(Marchi et al., 2007). Although we showed that atropine, as expected,
offered some protection against convulsions, no potentiation of the
PPR effect was demonstrated after the PPR+ATRP association. Previ-
ously (Maslanki et al., 1994), atropine was shown to be a potent inhib-
itor of pilocarpine-induced seizures, acting through M1 receptors. And
later, Bymaster et al. (2003) reported that muscarinic M1 receptors
appear to be the only muscarinic receptor subtype mediating seizures.
Thus, under our experimental conditions, other and more important
factors seem to be involved with PPR effects.
Evidences (Moldrich et al., 2003; Kong et al., 2012) indicate that
glutamate plays a crucial role in seizures initiation and propagation,
and abnormal glutamate release causes synchronous ﬁring of large
populations of neurons, leading to seizures. It has been hypothesized
that changes in glutamatergic transmission, in the perforant path,
promote the epileptogenic process and seizure generation. Enhanced
glutamatergic transmission, as evaluated by patch-clamp recordings in
rat hippocampal slices after pilocarpine-induced SE, was shown to
contribute to lowering the seizure threshold (Scimemi et al., 2006).
We showed that the memantine (a NMDA-type glutamate receptor
blocker) pretreatment was not able to prevent pilocarpine convulsions,
and its association to PPR did not potentiate the PPR anticonvulsive
action, suggesting that the glutamatergic transmission does not have
an important role in this drug effect.
It is widely accepted that voltage-gated calcium channels contrib-
ute to the control of excitability, at both cellular and neuronal network
levels. Thus, alterations in the expression or biophysical properties of
subtypes of calcium channels are implicated in the pathophysiology
underlying epileptic seizures, constituting important players in idio-
pathic generalized epilepsies (Cain and Snutch, 2010; Khosravani and
Zamponi, 2006). Both T-type and P/Q-type channels appear to be in-
volved in seizure genesis, modulation of network activity and genetic
seizure susceptibility (Zamponi et al., 2010). In order to assess the partic-
ipation of the Ca2+ in the anticonvulsive effect of PPR, nimodipine, a cal-
cium channel blocker, was administered alone or associated to PPR2.5
previously to the pilocarpine injection. Our results showed that in-
creases in latency to the 1st convulsion and latency to death were not
signiﬁcantly different among P350 groups, pretreated with nimodipine
or PPR, alone or associated, suggesting that calcium channels do not
play an important role in the PPR anticonvulsive action.
In recent years, the dysfunction of inhibitory GABAergic circuits
has been proposed as a cause for epilepsy, and studies performed on
both animal models and postmortem human samples indicate that
GABAergic neurons are altered in epilepsy (Sgadò et al., 2011). These
data suggest that the excitation/inhibition imbalance resulting from
defects inGABAergic circuitrymight represent a pathogenicmechanism
for epilepsy. Considering that pilocarpine-induced limbic seizures in
rodents are terminated by benzodiazepines, which are GABAA-receptor
positive modulators (Feng et al., 2008), we evaluated the possible
P350 group PPR10+P350 group PPR20+P350 group
Fig. 12. Representative photomicrographs (400×) showing that piperine treatments (PPR: 10 and 20 mg/kg, i.p.) reduced the number of hippocampal immunostained TNF-α cells,
in mice submitted to pilocarpine-induced convulsions. In the cases of PPR pretreatments, the animals were administered with PPR, followed by the pilocarpine injection
(P: 350 mg/kg, i.p.), 30 min later. Hippocampi were dissected up to 30 min (or immediately after death) after the 1st convulsion, in the P350 group, and sacriﬁced 2 h later in
the PPR+P350 groups. Piperine pretreatments at both doses (10 and 20 mg/kg, i.p.) reduced immunostainings for TNF-α (PPR10+P350 and PPR20+P350 groups, middle and
left columns), as related to the P350 group (right column). The PPR effect was mainly observed in hippocampal CA1, CA3 and DG areas (three upper rows, from top to bottom, re-
spectively). In the cortex, the TNF-α immunostained cells were still present in the PPR5+P350 group (fourth row).
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For that, P350 groups pretreated with the association of PPR with
DZP showed a further increase in the latency to the 1st convulsion, ascompared to the effects of each drug separately. Besides, in the associat-
ed group, 50% of the animals did not convulse and 100% survived,
suggesting that DZP potentiates the PPR anticonvulsive effect.
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nist, in association with PPR did not alter latency to the 1st convulsion
or latency to death, it signiﬁcantly blocked increases in these parameters,
as observedwith the PPR5+P350 group. It has been shown that the sys-
temic administration of ﬂumazenil completely reverses the diazepam-
evoked anticonvulsant action, in the model of pilocarpine-induced
seizures in rats (Khan et al., 2000). These authors conclude that the di-
azepam anticonvulsant action is mediated by the benzodiazepine–
GABAA-receptor complex, what could also be the case under our exper-
imental conditions.
Furthermore, while in the untreated P350 group there was a sig-
niﬁcant decrease in striatal DA contents and increase in its DOPAC
and HVA metabolites, as related to normal controls, these effects were
not altered by the PPR pretreatment. In addition, changes in DA induced
by PPR alone were much smaller. Previously (Nascimento et al., 2005),
we showed that striatal contents of DA decreased while HVA increased,
in pilocarpine-induced SE in rats. Additionally, decreases in DA andHVA
contents were observed in the cortex of epileptic rats (Freitas et al.,
2006). Evidences (Clinckers et al., 2005) demonstrated that DA and
5-HT exert anticonvulsant effects against limbic seizures in rats, and
the anticonvulsant activity was always accompanied by signiﬁcant
increases in DA and 5-HT levels in the hippocampus. Other ﬁndings
(D'Hooge et al., 1996) suggest that DA differentially modulates the
seizure threshold in the forebrain, acting via D1 mechanisms in the
substantia nigra and via D2 mechanisms in the striatum. Since PPR did
not reverse P350-induced decreases in striatal DA contents, dopaminer-
gic mechanisms are probably not involved with the PPR anticonvulsant
action.
Seizures are evoked in freely moving rats by intra-hippocampal
micro-perfusion of 10 mM pilocarpine, increasing hippocampal glu-
tamate, GABA, DA and 5-HT concentrations during seizures (Meurs
et al., 2008). DA and 5-HT have been shown to exert anticonvulsant
effects against limbic seizures in rats, mediated by D2 and 5-HT1A re-
ceptors stimulation. For exogenously administered monoamines, the
anticonvulsant activity was only observed following high increases
in baseline levels (Clinckers et al., 2005). In pilocarpine-evoked sei-
zures in rats, the anticonvulsant activities of oxcarbazepine and its
metabolite were always accompanied by signiﬁcant increases in DA
and 5-HT.
Excitatory amino acids such as glutamate and aspartate are involved
in the generation and expression of epileptic seizures in themammalian
brain. After its interaction with the NMDA-subtype of glutamate recep-
tor, glutamate induces the Ca2+ inﬂux, increasing the neuronal nitric
oxide synthase (nNOS) activity and nitric oxide (NO) production. On
the other hand, inhibitory amino acids such as GABA and glycine coun-
teract the neuronal excitation. GABA, acting through the GABAA recep-
tor, increases the chloride inﬂux, leading to hyperpolarization of the
cell membrane and antagonism of epileptic seizures.
In the present work, we showed that although P350 decreased
striatal glutamate levels, it did not alter aspartate contents, and these
effects were maintained in the PPR pretreated group.While no changes
were seen in GABA levels in the untreated P350 group, these values
were increased by more than twice in P350 groups treated with the
lower PPR doses. P350 decreased glycine levels, as compared to normal
controls, and these values were more than doubled in the PPR+P350
groups. Our data suggest that inhibitory but not excitatory amino
acids are involved in the anticonvulsant action of PPR. An earlier study
postulated that the GABA antagonism exerted by GCs could underlie
their epileptogenic character (D'Hooge et al., 1996). Others found
that the excitatory effects of GCs on the CNS may be explained by the
activation of NMDA receptors and concomitant inhibition of GABA re-
ceptors (Meurs et al., 2008).
Furthermore, while in the P350 group signiﬁcant increases in ni-
trite contents were seen in the blood and the brain cortex, as related
to normal controls, the PPR pretreatment decreased these values to-
wards those of normal controls. Evidences have associated the useof piperine with a reduction of both inﬂammation and oxidative
stress, in several experimental models (Diwan et al., 2011; Pathak
and Khandelwal, 2007; Vijayakumar and Nalini, 2006; Vijayakumar
et al., 2004). On the other hand, excessive free radicals production
has been implicated in the pathogenesis of various neurological disor-
ders, including epilepsy. Thus, the ability of antioxidants for reducing
seizure manifestations, and the accompanying biochemical changes
further support a role for free radicals in seizures (Devi et al., 2008;
Shin et al., 2011). Therefore, the antioxidant property of PPR shows
its potential for neuroprotection, and highlights its possible role as an
adjunct to antiepileptic drugs for better seizure control.
We showed that, while pilocarpine signiﬁcantly increased the num-
ber of hippocampal TNF-α immunostained cells, indicating the pres-
ence of inﬂammation, this effect was blocked in groups pretreated
with piperine. Inﬂammation is known to be an important factor in
the pathophysiology of seizure generation and epileptogenesis (Riazi
et al., 2010). In addition, a variety of factors inﬂuence the incidence
and prevalence of seizures and, among those, cytokines play an impor-
tant role. Thus, cytokines as TNF-α are known to be rapidly induced in ro-
dent brains, during epileptic activity (Rao et al., 2009). An earlier study
(Bock et al., 1996) showed the release of TNF-α in the rat hippocampus,
following epileptic seizures, while another (Lim et al., 2006) demon-
strated that seizure activities cause the elevation of proinﬂammatory
cytokines, and activate inﬂammatory reactions.
Epileptic seizures were shown to induce an inﬂammatory re-
sponse within the brain, through activation of microglia and produc-
tion of proinﬂammatory cytokines (Vezzani and Granata, 2005; Vezzani
et al., 2008). Furthermore, considering that piperine presents an anti-
inﬂammatory property and decreases the number of brain TNF-α-
producing cells, these two actions are certainly involved with its
anticonvulsant activity. As already observed by us, other drugs also
exert anticonvulsant actions and neuroprotection against pilocarpine-
induced convulsions, by means of their antioxidant effect and modula-
tion of brain amino acids (Nogueira et al., 2011).
In conclusion, piperine anticonvulsant effects do not have a single
mechanismof action, but instead seem to be the result of the association
ofmany factors. Among those are its anti-inﬂammatory and antioxidant
properties, manifested by in vivo and in vitromodels. Furthermore, PPR
may also act by modulating/activating the GABA neurotransmission, as
well as increasing brain inhibitory amino acid levels in the striatum,
making the participation of these events in the PPR action a strong
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